AlphaTON's Cyncado Therapeutics and Australia's ADDRI to Launch Investigator-Initiated Mesothelioma Clinical Trial of TT-4, Complementing U.S. Plans

Core Insights - AlphaTON Capital Corp and its subsidiary Cyncado Therapeutics announced a non-binding Letter of Intent for a clinical trial of TT-4 in mesothelioma, sponsored by ADDRI in Australia [1][2] - The trial aims to enroll approximately 50 patients and addresses the urgent need for second-line therapies in mesothelioma, where current outcomes are poor [2][5] - Cyncado will provide TT-4 and limited support under a definitive agreement, as part of an international program alongside U.S. activities [2] Clinical Trial Details - The investigator-initiated trial will evaluate TT-4, a selective A2B receptor antagonist, in mesothelioma patients [1][2] - The trial is led by A/Prof Steven Kao and Dr. Melvin Chin, both specialists in mesothelioma care and research [3][4] - The trial is significant due to Australia's high per-capita burden of mesothelioma, making it a compelling location for research [2][6] Company Background - Cyncado Therapeutics is focused on developing small molecule adenosine receptor antagonists to overcome immune suppression in oncology, with TT-4 as its lead program [11] - The company aims to advance TT-4 toward first-patient dosing in Q1 2026, with a focus on generating decision-quality data for better patient outcomes [11][2] - ADDRI is a not-for-profit research institute dedicated to reducing the impact of asbestos-related diseases and is recognized as a WHO Collaborating Centre [6]